Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plus Peginterferon alpha-2b in GIST
NCT00585221Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2007
- Primary completion
- Jul 2009
- Countries
- 1
- Sponsor
- University of Utah
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Conditions
- gastrointestinal stromal tumor (GIST)
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in gastrointestinal stromal tumor (GIST), sponsored by University of Utah. Primary endpoints: Decrease in Tumor Size at 18 months and Time to Progression at 2 years. Started Jul 2007; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
All patients
Peginterferon alfa-2b + Imatinib
03
Endpoints
Primary
Decrease in Tumor Size
Time to Progression
Beyond the preview
Go deeper on NCT00585221.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585221.